Royal Bank of Canada’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-362
| Closed | -$2K | – | 7782 |
|
|
2024
Q1 | $2K | Buy |
362
+317
| +704% | +$1.97K | ﹤0.01% | 6734 |
|
|
2023
Q4 | $0 | Buy |
45
+14
| +45% | +$123 | ﹤0.01% | 7768 |
|
|
2023
Q3 | $0 | Sell |
31
-4
| -11% | -$80 | ﹤0.01% | 7799 |
|
|
2023
Q2 | $1K | Sell |
35
-68
| -66% | -$2.09K | ﹤0.01% | 7147 |
|
|
2023
Q1 | $3K | Sell |
103
-127
| -55% | -$5.91K | ﹤0.01% | 6727 |
|
|
2022
Q4 | $8K | Buy |
230
+161
| +233% | +$19.3K | ﹤0.01% | 6628 |
|
|
2022
Q3 | $16K | Buy |
69
+32
| +86% | +$7.87K | ﹤0.01% | 6242 |
|
|
2022
Q2 | $7K | Sell |
37
-54
| -59% | -$10.9K | ﹤0.01% | 6544 |
|
|
2022
Q1 | $22K | Sell |
91
-145
| -61% | -$22.9K | ﹤0.01% | 6561 |
|
|
2021
Q4 | $37K | Buy |
236
+80
| +51% | +$15.5K | ﹤0.01% | 6544 |
|
|
2021
Q3 | $31K | Buy |
156
+58
| +59% | +$13.8K | ﹤0.01% | 6452 |
|
|
2021
Q2 | $25K | Sell |
98
-11
| -10% | -$2.75K | ﹤0.01% | 6455 |
|
|
2021
Q1 | $29K | Buy |
109
+15
| +16% | +$4.73K | ﹤0.01% | 6216 |
|
|
2020
Q4 | $34K | Buy |
94
+69
| +276% | +$19.8K | ﹤0.01% | 5825 |
|
|
2020
Q3 | $6K | Hold |
25
| – | – | ﹤0.01% | 6103 |
|
|
2020
Q2 | $7K | Buy |
25
+3
| +14% | +$884 | ﹤0.01% | 5966 |
|
|
2020
Q1 | $5K | Sell |
22
-62
| -74% | -$19.8K | ﹤0.01% | 6061 |
|
|
2019
Q4 | $37K | Buy |
+84
| New | +$29.8K | ﹤0.01% | 5591 |
|
|
2019
Q3 | – | Sell |
-11
| Closed | -$4K | – | 7244 |
|
|
2019
Q2 | $4K | Buy |
+11
| New | +$3.81K | ﹤0.01% | 6419 |
|
|
2018
Q4 | – | Sell |
-1
| Closed | – | – | 7227 |
|
|
2018
Q3 | $0 | Buy |
+1
| New | +$342 | ﹤0.01% | 7025 |
|
|
2018
Q2 | – | Hold |
0
| – | – | – | 6845 |
|
|
2017
Q2 | – | Sell |
-5
| Closed | -$2K | – | 6837 |
|
|
2017
Q1 | $2K | Sell |
5
-6
| -55% | -$2.07K | ﹤0.01% | 6448 |
|
|
2016
Q4 | $4K | Buy |
+11
| New | +$4.03K | ﹤0.01% | 6372 |
|
|
2015
Q2 | – | Sell |
-11
| Closed | -$91K | – | 6762 |
|
|
2015
Q1 | $91K | Buy |
+11
| New | +$96.2K | ﹤0.01% | 4665 |
|
|
2014
Q4 | – | Hold |
0
| – | – | – | 6335 |
|
|
2014
Q3 | – | Hold |
0
| – | – | – | 6171 |
|
|
2014
Q2 | – | Hold |
0
| – | – | – | 5741 |
|
Other funds holding EIGR
Royal Bank of Canada's EIGR Position: Q2 2024 in Review
Royal Bank of Canada sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2024, closing a stake of 362 shares — an estimated $2K sold.
Royal Bank of Canada first reported a position in EIGR in Q1 2015 and held it in 23 quarters. The position peaked at $91K in Q1 2015. 2 funds tracked by Wall St. Rank hold EIGR as of Q2 2024.
- Royal Bank of Canada reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
- Royal Bank of Canada sold 362 Eiger BioPharmaceuticals, Inc. shares in Q2 2024, an estimated $2K.
- Royal Bank of Canada first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2015 and held it in 23 quarters.
- Royal Bank of Canada's Eiger BioPharmaceuticals, Inc. position peaked at $91K in Q1 2015.
- 2 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2024.
Based on Royal Bank of Canada's 13F filing for Q2 2024, filed 14 Aug 2024.